ALK and non-small cell lung carcinoma: In patients harboring ALK fusions, various ALK TKIs could be used in the clinical treatment of advanced NSCLC patients, such as crizotinib (43), alectinib (44–46), brigatinib (47, 48), ceritinib (49, 50), lorlatinib (51), ensartinib (52), and repotrectinib (53).